Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors

As cancer immunotherapy using immune checkpoint inhibitors (ICIs) is rapidly evolving in clinical practice, it is necessary to identify biomarkers that will allow the selection of cancer patients who will benefit most or least from ICIs and to longitudinally monitor patients’ immune responses during...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ho Jung, Chon, Hong Jae, Kim, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430528/
https://www.ncbi.nlm.nih.gov/pubmed/34502325
http://dx.doi.org/10.3390/ijms22179414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430528/
https://www.ncbi.nlm.nih.gov/pubmed/34502325
http://dx.doi.org/10.3390/ijms22179414

Ejemplares similares